Clinical Trial Update: Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder [NA]

View source ↗

Summary

A clinical trial update indicates that oral ganglioside supplementation is being studied to treat GM3 Synthase Deficiency, a rare metabolic disorder, with the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm3 Synthase Deficiency

Drugs mentioned

• Ganglioside oral supplement (ganglioside)

Snippet

Sponsor: DDC Clinic - Center for Special Needs Children | Conditions: GM3 Synthase Deficiency | NA | Status: UNKNOWN